Dynavax Technologies
2100 Powell Street
Suite 300
Emeryville
California
94608
United States
Tel: 510-848-5100
Fax: 510-848-1379
Website: http://www.dynavax.com/
Email: contact@dynavax.com
About Dynavax Technologies
We are developing immunotherapies based on cutting-edge Toll-like receptor (TLR) biology and its ability to modulate the immune system.
463 articles about Dynavax Technologies
-
Dynavax Technologies Corporation to Present at Bear Stearns 20th Annual Healthcare Conference
9/7/2007
-
Dynavax Technologies Corporation Issued Landmark Patent Covering Second-Generation TLR9 Agonists
8/16/2007
-
Dynavax Technologies Corporation Awarded $3+ Million Universal Flu Vaccine Grant from National Institute of Allergy And Infectious Diseases (NIAID)
8/7/2007
-
Dynavax Technologies Corporation Loss Grows on Clinical Trial Costs
8/1/2007
-
Dynavax Technologies Corporation Announces Second Quarter 2007 Financial Results
7/31/2007
-
Dynavax Technologies Corporation Gets $30 Million Financing for Allergy Program
7/19/2007
-
Dynavax Technologies Corporation Completes Enrollment of HEPLISAV(TM) Phase 3
7/12/2007
-
Coley Pharmaceutical Group Grants Dynavax Technologies Corporation (Jobs) License for Commercialization of HEPLISAV(TM); Coley to Receive $5.0 Million Upfront
6/29/2007
-
Dynavax Technologies Corporation Starts HEPLISAV(TM) Phase 3 in Europe; U.S. Study; and Phase 2 in ESRD in Canada
6/27/2007
-
Dynavax Technologies Corporation to Present at the Sixth Annual Needham Biotechnology & Medical Technology Conference
6/12/2007
-
Dynavax Technologies Corporation to Present at the Third Annual Bear Stearns Biotech Confab
6/5/2007
-
Dynavax Technologies Corporation to Present at the Bank of America 2007 Health Care Conference
5/30/2007
-
Dynavax Technologies Corporation Announces First Quarter 2007 Financial Results
5/3/2007
-
Dynavax Technologies Corporation to Present at CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference
4/6/2007
-
Dynavax Technologies Corporation Initiates Phase I Trial of Hepatitis B Therapy
3/1/2007
-
The Day In Review: Genentech, Inc. Extends Uses For Avastin And Xeloda
2/23/2007
-
Dynavax Technologies Corporation Reports Interim, One-Year Data From Ragweed Allergy Trial At AAAAI
2/23/2007
-
Dynavax Technologies Corporation Provides 2007 Financial Outlook
2/23/2007
-
Dynavax Technologies Corporation Announces Webcast On AAAAI Data And 2007 Financial Outlook
2/23/2007
-
Dynavax Technologies Corporation Announces Fourth Quarter And Year End 2006 Financial Results
2/14/2007